Skip to content
Peptides Codex
ENFR

Use the arrow keys to choose a result, Enter to open it, and Escape to close.

← Home
Blends explained

What Is the “GLOW” Peptide? GHK-Cu + BPC-157 + TB-500, Explained From the Evidence

“GLOW peptide” is a vendor blend name for GHK-Cu, BPC-157 and TB-500 in one vial. This guide explains each component, the linked cellular and animal evidence, the gaps for a three-way injectable blend, and product-specific authorization.

By The Peptides Codex Editorial TeamReviewed September 7, 2026

What the name means

“GLOW” is a marketing name, not a molecule. In the grey-market peptide trade it refers to a single vial containing three research peptides — GHK-Cu (a copper-binding tripeptide with a cosmetic-science literature), BPC-157 and TB-500 — sold with claims about skin, hair and recovery. The name presumably comes from GHK-Cu's association with skin appearance. As with every blend, the ratio is whatever the vendor chose and is stated only on the label. The three components have their own profiles on this site; this guide distinguishes the blend from the evidence about its components.

What is in a “GLOW” vial
ComponentWhat it isHuman evidenceRegulatory status
GHK-CuTripeptide Gly-His-Lys complexed with copper(II); naturally present in plasma, declining with ageCited primary sources are cellular and animal; do not establish human injectable benefitPermitted as a cosmetic ingredient; not approved as a drug
BPC-15715-residue synthetic gastric-derived fragmentNo randomized human efficacy trial in cited sourcesNot approved; FDA barred from compounding (2023)
TB-5007-residue fragment of thymosin β4None for the fragmentNot approved; WADA-prohibited

What the GHK-Cu skin research establishes

Primary studies cited here show effects of GHK-Cu on collagen in cultured fibroblasts and on experimental wounds in animals. Those endpoints do not establish the effectiveness of a topical commercial formulation or of an injected blend in humans. The exposure route, formulation and population matter; the sources here do not establish human injectable safety or a skin or hair benefit from GLOW.

BPC-157 and TB-500: preclinical only

BPC-157's literature is almost entirely rodent injury models from a single group; its human data are limited uncontrolled human reports. TB-500 is a synthetic 7-residue fragment of thymosin β4 with no human trials; the full-length protein has small trials in eye and cardiac indications. Neither has any published data on skin, hair or “glow” endpoints in humans. The Wolverine guide, which covers the same two peptides, goes through the evidence and the 2023 FDA compounding decision.

Why a three-way blend is a different question again

Even if each component had solid data, a fixed-ratio mixture would need its own study, because doses, kinetics and interactions cannot be inferred from the parts. No such study exists. Beyond efficacy, there is a chemistry problem specific to GLOW: GHK-Cu carries copper(II), a redox-active metal ion, and copper can catalyse oxidation of methionine, histidine and cysteine residues in other peptides. Whether copper in a shared vial degrades BPC-157 or TB-500 over time has not been published either way. Independent testing of grey-market vials has repeatedly found content that does not match the label.

Legal and safety status

Health Canada has warned about unauthorized injectable peptides sold online, including products described with these ingredient names. Its warning concerns Canadian products and does not establish every jurisdiction's approval status. Check the particular regulator, product and indication. A research label does not demonstrate safety, quality or authorization, and the sources here do not establish human safety of a marketed blend.

Reading the claims responsibly

The sources cited here do not establish authorization, human efficacy or safety for the marketed blend. “Research use only” labelling does not change that. This page explains what the name refers to; it is not guidance on obtaining or using any product.

Sources and what they cover

These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.

  1. Maquart et al. (1988) — GHK-Cu and collagen synthesis in fibroblast cultures

    Cell-culture collagen endpoint, not a human injectable skin or hair trial.

    Relevant sections: What the GHK-Cu skin research establishes

  2. Maquart et al. (1993) — GHK-Cu in experimental wound models

    Animal wound model; cosmetic formulation and human systemic exposure require separate evidence.

    Relevant sections: What the GHK-Cu skin research establishes

  3. Cerovecki et al. (2010) — BPC-157 and ligament healing in rats

    Rat injury model; cannot establish benefit or a safe route of administration in humans.

    Relevant sections: BPC-157 and TB-500: preclinical only

  4. Rahaman et al. (2024) — TB-500 metabolites, analytical testing and in-vitro wound assays

    In-vitro and rat work on TB-500. Results for full-length thymosin beta-4 are a separate evidence base.

    Relevant sections: BPC-157 and TB-500: preclinical only

  5. Health Canada (2026) — unauthorized injectable peptides bought online

    Canadian safety and authorization notice for the products described. It does not establish approval status in every country.

    Relevant sections: Legal and safety status

FAQ

What is the GLOW peptide?+

A vendor blend name for GHK-Cu, BPC-157 and TB-500 in one vial. It is not a single peptide and not an approved product.

What does GLOW peptide do?+

Nothing has been demonstrated for the blend. The cited GHK-Cu experiments are cellular and animal; they do not establish human benefit from the three-way blend.

Is GLOW peptide safe?+

Unknown. No safety study exists for the blend, and grey-market vials are frequently mislabelled. Injected GHK-Cu has no human safety characterisation.

What is the difference between GLOW and KLOW?+

KLOW adds a fourth peptide, KPV, to the same three components.

Is GHK-Cu approved?+

Cosmetic ingredient use and drug authorization are distinct. The cited sources do not establish authorization or safety of injectable GHK-Cu products.

Related peptide profiles

GHK-Cu
Cosmetic / research peptide
GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, a tripeptide found in human plasma at about 200 ng/mL at age 20 and 80 ng/mL by 60. It has a wide cell and animal literature on collagen synthesis, wound repair and anti-inflammatory signalling, a cosmetic market built on it, and — as a 2025 review notes — a surprising absence of clinical studies. Topical use is permitted as a cosmetic; it is not an approved drug.
BPC-157
Research pentadecapeptide (gastric-juice-derived sequence)
BPC-157 (Body Protection Compound-157) is a synthetic 15-residue peptide, GEPPPGKPADDAGLV, derived from a sequence found in human gastric juice. Hundreds of rodent studies, most from a single Zagreb group, report accelerated healing of tendon, muscle, ligament, gut and skin injuries via VEGFR2, nitric-oxide and ERK1/2 pathways. Human evidence is limited to a small safety study and a retrospective chart review; the first phase 2 efficacy trial began recruiting in 2026. It is not approved anywhere and the FDA barred it from compounding in 2023.
TB-500
Synthetic thymosin β4 fragment (research peptide)
TB-500 is the synthetic, N-acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), corresponding to residues 17–23 of thymosin β4, the protein's actin-binding motif. It first appeared as a veterinary preparation and is sold as a research chemical; its metabolism has been characterised in rats. A 2026 rat tendon study reported benefits with vendor-labelled TB-500 whose sequence was not characterized, so it does not establish efficacy of Ac-LKKTETQ. The fragment has no published human efficacy data. No product-specific authorization record has been verified in this profile; human trial registration does not establish approval. Its first registered human trial began recruiting in 2026.
KPV
Research peptide
KPV is the tripeptide Lys-Pro-Val, the C-terminal fragment of α-melanocyte-stimulating hormone. At nanomolar concentrations it inhibits NF-κB and MAPK inflammatory signalling in cells, and oral KPV reduced chemically induced colitis in mice through the PepT1 transporter (Dalmasso et al., Gastroenterology 2008). It has no human trials and is not an approved medicine.

More guides

Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Regulations vary by jurisdiction.
You might also like: All guides · Encyclopedia · Tools · FAQ
Cite this: Peptides Codex — What Is the “GLOW” Peptide? GHK-Cu + BPC-157 + TB-500, Explained From the Evidence
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.